-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBV-IN-9
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2170998-69-1.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2170998-69-1 |
| Description | HBV-IN-9, a potent HBsAg (HBV Surface antigen) inhibitor (IC50 = 10 nM), is an HBV DNA production inhibitor with an IC50 of 0.15 nM in HepG2.2.15 cells. (Extracted from patent WO2018001952A1, example 20) |
Product Information
| Synonyms | Pyrido[4,3-d]pyrimidine, 6-[6-fluoro-4-(3-methoxy-1-pyrrolidinyl)-2-pyridinyl]-5,6,7,8-tetrahydro-5-methyl-2-(2-pyrimidinyl)- |
| IUPAC Name | 6-[6-fluoro-4-(3-methoxypyrrolidin-1-yl)pyridin-2-yl]-5-methyl-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine |
| Molecular Weight | 421.47 |
| Molecular Formula | C22H24FN7O |
| Canonical SMILES | CC1C2=CN=C(N=C2CCN1C3=NC(=CC(=C3)N4CCC(C4)OC)F)C5=NC=CC=N5 |
| InChI | InChI=1S/C22H24FN7O/c1-14-17-12-26-22(21-24-6-3-7-25-21)27-18(17)5-9-30(14)20-11-15(10-19(23)28-20)29-8-4-16(13-29)31-2/h3,6-7,10-12,14,16H,4-5,8-9,13H2,1-2H3 |
| InChIKey | XTZQFRYMZIPXRY-UHFFFAOYSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 594 |
| Exact Mass | 421.20263658 |
| Target | HBV |
| XLogP3-AA | 2.1 |
